Current reports
Current Report No. 2/2026 – Summary of the FDA Type B Meeting for CPL’36 in the Treatment of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease (PD-LID)
Legal basis: Article 17 of the MAR Regulation – Inside Information, 5:13 p.m. The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that on February 13, 2026, it completed its analysis of the written responses received from the U.S. Food and Drug Administration (“FDA”) to the questions submitted in the background package asRead more »
Current Report No. 1/2026 – Dates of publication of periodic reports in 2026
Legal basis: Article 52(2)(1) of the Act on Public Offering – current and periodic information. Acting pursuant to § 84(1) of the Regulation of the Minister of Finance of 6 June 2025 on current and periodic information disclosed by issuers of securities …, the Management Board of Celon Pharma S.A. (the “Issuer”) hereby announces theRead more »
Current report 18/2025 – Registration of an Amendment to the Company’s Articles of Association
Date of preparation: October 10, 2025 Legal basis: Article 56(1)(2) of the Act on Public Offering – current and periodic information Report content: The Management Board of Celon Pharma S.A. (the “Company”, the “Issuer”) hereby informs that on October 10, 2025, the District Court for the Capital City of Warsaw in Warsaw, 14th Commercial DivisionRead more »
Current Report No. 17/2025 – Execution of an Agreement by a Subsidiary with the General Contractor of the Investment Project,
Date: 3 October 2025, 17:07 Legal basis: Article 17(1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council (MAR) – inside information The Management Board of Celon Pharma S.A. (the “Company”, the “Issuer”) announces that on 3 October 2025 the Issuer’s subsidiary – Celon Pharma Slovakia s.r.o. (“Celon Pharma Slovakia”, theRead more »
Current report 16/2025 – Summary of Type B Meeting with the Food and Drug Administration (FDA) for CPL’36 in the treatment of schizophrenia
Legal basis: Art. 17 of the MAR Regulation – Inside information Report content: The Management Board of Celon Pharma S.A. (the “Company”, the “Issuer”) informs that on October 2, 2025, the Company received a summary of the Type B meeting held on October 1, 2025, containing responses to questions submitted for the combined pre-IND andRead more »
Current Report No. 14/2025 – Agreement with the European Bank for Reconstruction and Development on the principal terms of financing for a subsidiary in connection with project implementation
Subject: Agreement with the European Bank for Reconstruction and Development on the principal terms of financing for a subsidiary in connection with project implementationLegal basis: Article 17(1) of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation – MAR) – inside informationDateRead more »
Current Report No. 7/2025 – Execution of agreements on support for two Celon Pharma S.A. projects under the National Recovery and Resilience PlanLegal basis:
Subject: Execution of agreements on support for two Celon Pharma S.A. projects under the National Recovery and Resilience PlanLegal basis: Article 17(1) of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation – MAR) – inside informationDate and time of disclosure: 29Read more »
Current Report No. 8/2025 – Execution of agreement on support for a Celon Pharma S.A. project under the National Recovery and Resilience Plan
Subject: Execution of agreement on support for a Celon Pharma S.A. project under the National Recovery and Resilience PlanLegal basis: Article 17(1) of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation – MAR) – inside informationDate and time of disclosure: 6Read more »
Current report 4/2025 – Phase II top – line results for CPL’ 36, a PDE10a inhibitor in the treatment of Dyskinesia in Parkinson’s disease
Legal basis Art. 17 section 1 MAR – confidential information. Report content: In reference to current report 17/2024 regarding positive results of the Phase II clinical trial on a drug based on CPL’36, an innovative PDE10A inhibitor, in the treatment of schizophrenia, in which the Company informed about the simultaneous ongoing Phase II clinical trialRead more »